Roche has asked the European Medicines Agency to fast-track its planned EU marketing authorization application (MAA) for another of its investigational T-cell engaging bispecific antibodies, glofitamab.
Glofitamab is being developed to treat relapsed or refractory (r/r) diffuse large B-cell lymphomas (DLBCL), high grade B cell lymphoma...








